# OnCo record chrysalis (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/chrysalis/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "chrysalis", "NCT02609776" ;
  schema:name "CHRYSALIS"@en ;
  schema:description "CHRYSALIS was the first human study of amivantamab, an antibody that grabs both EGFR and MET; its cohort of people with EGFR exon 20 insertion lung cancer responded well enough to earn the drug its first approval."@en ;
  schema:url <https://onco.cc/trials/chrysalis/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02609776> ;
  onco:status "active" ;
  onco:tag "subtype-trials" ;
  onco:phase "1" ;
  onco:cancers <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:drugs <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/lazertinib/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:people <https://onco.cc/people/keunchil-park/> .